The PDUFA date is May 29, 2026 — two days from this release. Traders should position for binary outcome: approval would open a large new pediatric market (first needle-free insulin option in 100+ years) and likely drive significant upside. Rejection would be a major setback. The ADA data presentations provide supportive clinical context ahead of the decision.
Price Chart
Executive Summary
MannKind announced nine poster presentations at ADA 2026 covering Afrezza data in pediatric efficacy, treatment satisfaction, AID algorithm use, and gestational diabetes. The PDUFA target action date for Afrezza in pediatric patients (ages 4-17) is May 29, 2026, just two days after this press release. The data broadly support Afrezza's profile but the key catalyst is the upcoming FDA decision on pediatric approval.
Key Facts
- PDUFA target action date for Afrezza pediatric indication (ages 4-17) is May 29, 2026
- Nine poster presentations at ADA 2026 (June 5-8) including pediatric A1c, treatment satisfaction, AID algorithm, and gestational diabetes data
- If approved, Afrezza would be the first needle-free insulin option for pediatric patients in over 100 years
- FDA accepted sBLA for review in October 2025
- Afrezza is already approved for adults (age 18+) since June 2014 and in India and Brazil
Financial Impact
Pediatric approval would expand Afrezza's addressable patient population significantly; no specific revenue estimates provided
Risk Factors
- FDA may issue a Complete Response Letter (CRL) on safety/efficacy grounds, particularly given the boxed warning for bronchospasm and lung function decline in adults
- Pediatric population has additional safety considerations (lung development, hypoglycemia risk) that could delay or block approval
- Afrezza has a history of slow commercial adoption in adults; pediatric uptake may also be gradual
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302065 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | Press Release | $3.85 $4.09 | ▲ +6.23% | ▲ +1.21% | $3.74 (−2.86%) |
Jul 24, 2026 9w ago | 8-K | $3.95 $4.07 | ▲ +3.04% | ▼ −0.26% | $3.74 (−5.32%) |
Jul 18, 2026 10w ago | Insider Cluster | $3.98 $3.90 | ▼ −2.01% | ▼ −6.13% | $3.74 (−6.03%) |
Jun 3, 2026 17w ago | Press Release | $3.36 $4.52 | ▲ +34.52% | ▲ +35.52% | $3.74 (+11.31%) |
Jun 2, 2026 17w ago | 8-K | $3.43 $4.05 | ▲ +18.08% | ▲ +19.64% | $3.74 (+9.04%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.74 (−0.80%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.74 (−0.80%) |
May 28, 2026 18w ago | 8-K | $3.64 $4.14 | ▲ +13.74% | ▲ +16.88% | $3.74 (+2.75%) |
May 27, 2026 18w ago | Press Release | $3.55 $3.93 | ▲ +10.70% | ▲ +12.61% | $3.74 (+5.35%) |
May 12, 2026 20w ago | Insider Cluster | $3.28 $3.63 | ▲ +10.67% | ▲ +12.40% | $3.74 (+14.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access